TELA Bio, Inc. (NASDAQ:TELA) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET

Company Participants

Louisa Smith - Vice President of Gilmartin Group
Antony Koblish - Co-founder, President & CEO
Roberto Cuca - COO & CFO

Conference Call Participants

Frank Takkinen - Lake Street Capital Markets
Caitlin Cronin - Canaccord Genuity
Michael Sarcone - Jefferies
Matthew O'Brien - Piper Sandler
David Turkaly - Citizens JMP

Operator

Good afternoon, ladies and gentlemen, and welcome to the TELA Bio First Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. As a reminder, this conference call is being recorded.

I would now like to turn the conference over to Louisa Smith from the Gilmartin Group.

Louisa Smith

Thank you, Michelle, and good afternoon, everyone. Earlier today, TELA Bio released financial results for the first quarter of 2024. A copy of the press release is available on the company's website.

Joining me on today's call are Tony Koblish, President and Chief Executive Officer; and Roberto Cuca, Chief Operating Officer and Chief Financial Officer.

Before we begin, I'd like to remind you that during this conference call, the company may make projections and forward-looking statements regarding future events. We encourage you to review the company's past and future filings with the SEC, including, without limitation, the company's annual report on Form 10-K and quarterly reports on Form 10-Q, which identify the specific factors that may cause actual results or events to differ materially from those described in these forward-looking statements.

These factors may include, without limitation, statements regarding product development and pipeline opportunities, product potential, the impact of various macroeconomic conditions identified in our filings, the regulatory environment, sales and marketing strategies, capital resources or operating performance.

With that, I will now turn the call over to Tony.

Antony Koblish

Thank you, Louisa, and good afternoon, everyone. Thank you for joining us for TELA Bio's first quarter 2024 earnings call. In this call, I'd like to highlight some critical milestones we hit in the quarter as well as update you on our continued strategic progress and ongoing growth opportunities. We've started the year off strong. First quarter revenue was $16.6 million, representing 39% growth over the same period in 2023 and our 13th consecutive quarter with growth of 35% or greater.

We are capitalizing on the considerable momentum we generated in the fourth quarter, and our business is firing on all cylinders. As you will hear today, we are benefiting from the recent enhancements to our commercial team in addition to some key product launches that will enable us to drive significant growth through the remainder of the year.